LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 763

Search options

  1. Book ; Online ; E-Book: Clinical neurovirology

    Nath, Avindra / Berger, Joseph R.

    2020  

    Author's details edited by Avindra Nath, Joseph R. Berger
    Keywords Electronic books
    Language English
    Size 1 Online-Ressource (xvii, 451 Seiten), Illustrationen
    Edition Second edition
    Publisher CRC Press
    Publishing place Boca Raton
    Publishing country United States
    Document type Book ; Online ; E-Book
    Remark Zugriff für angemeldete ZB MED-Nutzerinnen und -Nutzer
    HBZ-ID HT020469900
    ISBN 978-1-4987-3319-9 ; 978-1-315-11391-3 ; 9781498733168 ; 1-4987-3319-0 ; 1-315-11391-0 ; 1498733166
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    Kategorien

  2. Article: Commentary: Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies.

    Berger, Joseph R / Hartung, Hans-Peter

    Frontiers in neurology

    2023  Volume 14, Page(s) 1146027

    Language English
    Publishing date 2023-03-16
    Publishing country Switzerland
    Document type Journal Article ; Comment
    ZDB-ID 2564214-5
    ISSN 1664-2295
    ISSN 1664-2295
    DOI 10.3389/fneur.2023.1146027
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Amebic infections of the central nervous system.

    Berger, Joseph R

    Journal of neurovirology

    2022  

    Abstract: The report of death of a person from amebic meningoencephalitis, the proverbial "brain-eating ameba," Naegleria fowleri, acquired in a state park lake in Iowa in July 2022 has once again raised the seasonal alarms about this pathogen. While exceptionally ...

    Abstract The report of death of a person from amebic meningoencephalitis, the proverbial "brain-eating ameba," Naegleria fowleri, acquired in a state park lake in Iowa in July 2022 has once again raised the seasonal alarms about this pathogen. While exceptionally rare, its nearly universal fatality rate has panicked the public and made for good copy for the news media. This review will address free-living ameba that have been identified as causing CNS invasion in man, namely, Naegleria fowleri, Acanthamoeba species, Balamuthia mandrillaris, and Sappinia diploidea (Table 1). Of note, several Acanthamoeba spp. and Balamuthia mandrillaris may also be associated with localized extra-CNS infections in individuals who are immunocompetent and disseminated disease in immunocompromised hosts. These ameba are unique from other protozoa in that they are free-living, have no known insect vector, do not result in a human carrier state, and are typically unassociated with poor sanitation. Table 1 Free-living ameba that have been identified as causing CNS invasion in man, namely, Naegleria fowleri, Acanthamoeba species, Balamuthia mandrillaris, and Sappinia diploidea Entity Pathogenic ameba Predisposing disorders Portal of entry Incubation period Clinical features Radiographic findings CSF finding Diagnostic measures Primary amebic meningoencephalitis Naegleria fowleri; N. australiensis; N. italica Previously healthy children or young adults Olfactory epithelium 2-14 days (average 5 days) Headache, fever, altered mental status, meningeal signs; seizures Brain edema; meningeal enhancement; hydrocephalus; basal ganglia infarctions Increased opening pressure; neutrophilic pleocytosis (~ 1000 cells/cu mm); low glucose Brain biopsy, CSF wet prep, IIF culture or PCR Granulomatous amebic encephalitis Acanthamoeba spp.; Balamuthia mandrillaris; Sappinia diploidea Typically, immunocompromised individual Skin sinuses; olfactory epithelium respiratory tract Weeks to months Headache; altered mental status seizures, focal neurological findings Focal parenchymal lesions with edema; hemorrhagic infarctions; meningeal enhancement Generally, LP contraindicated; when performed lymphocytic pleocytosis; increased protein; low glucose Brain biopsy, CSF culture, wet prep, IIF, or PCR IIF indirect immunofluorescence, LP lumbar puncture, PCR polymerase chain reaction.
    Language English
    Publishing date 2022-09-13
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1283265-0
    ISSN 1538-2443 ; 1355-0284
    ISSN (online) 1538-2443
    ISSN 1355-0284
    DOI 10.1007/s13365-022-01096-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Reader Response: Acute Hypokinetic-Rigid Syndrome Following SARS-CoV-2 Infection.

    Berger, Joseph R

    Neurology

    2021  Volume 96, Issue 9, Page(s) 460

    MeSH term(s) COVID-19 ; Humans ; Hypokinesia ; SARS-CoV-2
    Language English
    Publishing date 2021-03-01
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 207147-2
    ISSN 1526-632X ; 0028-3878
    ISSN (online) 1526-632X
    ISSN 0028-3878
    DOI 10.1212/WNL.0000000000011535
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: PD-1 inhibition: a novel approach to the treatment of progressive multifocal leukoencephalopathy.

    Berger, Joseph R

    Annals of translational medicine

    2020  Volume 7, Issue Suppl 8, Page(s) S281

    Language English
    Publishing date 2020-01-03
    Publishing country China
    Document type Editorial ; Comment
    ZDB-ID 2893931-1
    ISSN 2305-5847 ; 2305-5839
    ISSN (online) 2305-5847
    ISSN 2305-5839
    DOI 10.21037/atm.2019.11.107
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Clinical commentary for "Progressive multifocal leukoencephalopathy on dimethyl fumarate with preserved lymphocyte count but deep T-cells exhaustion".

    Berger, Joseph R

    Multiple sclerosis (Houndmills, Basingstoke, England)

    2020  Volume 27, Issue 4, Page(s) 644–645

    MeSH term(s) Dimethyl Fumarate ; Humans ; Leukoencephalopathy, Progressive Multifocal/chemically induced ; Lymphocyte Count ; Lymphopenia ; T-Lymphocytes
    Chemical Substances Dimethyl Fumarate (FO2303MNI2)
    Language English
    Publishing date 2020-07-20
    Publishing country England
    Document type Journal Article ; Comment
    ZDB-ID 1290669-4
    ISSN 1477-0970 ; 1352-4585
    ISSN (online) 1477-0970
    ISSN 1352-4585
    DOI 10.1177/1352458520942209
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: COVID-19 and the nervous system.

    Berger, Joseph R

    Journal of neurovirology

    2020  Volume 26, Issue 2, Page(s) 143–148

    Abstract: A pandemic due to novel coronavirus arose in mid-December 2019 in Wuhan, China, and in 3 months' time swept the world. The disease has been referred to as COVID-19, and the causative agent has been labelled SARS-CoV-2 due to its genetic similarities to ... ...

    Abstract A pandemic due to novel coronavirus arose in mid-December 2019 in Wuhan, China, and in 3 months' time swept the world. The disease has been referred to as COVID-19, and the causative agent has been labelled SARS-CoV-2 due to its genetic similarities to the virus (SARS-CoV-1) responsible for the severe acute respiratory syndrome (SARS) epidemic nearly 20 years earlier. The spike proteins of both viruses dictate tissue tropism using the angiotensin-converting enzyme type 2 (ACE-2) receptor to bind to cells. The ACE-2 receptor can be found in nervous system tissue and endothelial cells among the tissues of many other organs.Neurological complications have been observed with COVID-19. Myalgia and headache are relatively common, but serious neurological disease appears to be rare. No part of the neuraxis is spared. The neurological disorders occurring with COVID-19 may have many pathophysiological underpinnings. Some appear to be the consequence of direct viral invasion of the nervous system tissue, others arise as a postviral autoimmune process, and still others are the result of metabolic and systemic complications due to the associated critical illness. This review addresses the preliminary observations regarding the neurological disorders reported with COVID-19 to date and describes some of the disorders that are anticipated from prior experience with similar coronaviruses.
    MeSH term(s) Angiotensin-Converting Enzyme 2 ; Betacoronavirus/genetics ; Betacoronavirus/metabolism ; Betacoronavirus/pathogenicity ; COVID-19 ; Coronavirus Infections/complications ; Coronavirus Infections/diagnosis ; Coronavirus Infections/epidemiology ; Coronavirus Infections/virology ; Encephalitis, Viral/complications ; Encephalitis, Viral/diagnosis ; Encephalitis, Viral/epidemiology ; Encephalitis, Viral/virology ; Headache/complications ; Headache/diagnosis ; Headache/epidemiology ; Headache/virology ; Host-Pathogen Interactions/genetics ; Humans ; Meningitis/complications ; Meningitis/diagnosis ; Meningitis/epidemiology ; Meningitis/virology ; Myalgia/complications ; Myalgia/diagnosis ; Myalgia/epidemiology ; Myalgia/virology ; Myositis/complications ; Myositis/diagnosis ; Myositis/epidemiology ; Myositis/virology ; Nervous System/pathology ; Nervous System/virology ; Pandemics ; Peptidyl-Dipeptidase A/genetics ; Peptidyl-Dipeptidase A/metabolism ; Pneumonia, Viral/complications ; Pneumonia, Viral/diagnosis ; Pneumonia, Viral/epidemiology ; Pneumonia, Viral/virology ; Protein Binding ; Receptors, Virus/genetics ; Receptors, Virus/metabolism ; SARS-CoV-2 ; Spike Glycoprotein, Coronavirus/genetics ; Spike Glycoprotein, Coronavirus/metabolism ; Stroke/complications ; Stroke/diagnosis ; Stroke/epidemiology ; Stroke/virology ; Virus Internalization
    Chemical Substances Receptors, Virus ; Spike Glycoprotein, Coronavirus ; spike protein, SARS-CoV-2 ; Peptidyl-Dipeptidase A (EC 3.4.15.1) ; ACE2 protein, human (EC 3.4.17.23) ; Angiotensin-Converting Enzyme 2 (EC 3.4.17.23)
    Keywords covid19
    Language English
    Publishing date 2020-05-23
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1283265-0
    ISSN 1538-2443 ; 1355-0284
    ISSN (online) 1538-2443
    ISSN 1355-0284
    DOI 10.1007/s13365-020-00840-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: PML with dimethyl fumarate-No role for natalizumab?

    Berger, Joseph R

    Multiple sclerosis (Houndmills, Basingstoke, England)

    2019  Volume 25, Issue 12, Page(s) 1686–1687

    MeSH term(s) Dimethyl Fumarate ; Humans ; Immunosenescence ; Leukoencephalopathy, Progressive Multifocal ; Lymphopenia ; Multiple Sclerosis ; Natalizumab
    Chemical Substances Natalizumab ; Dimethyl Fumarate (FO2303MNI2)
    Language English
    Publishing date 2019-08-22
    Publishing country England
    Document type Journal Article ; Comment
    ZDB-ID 1290669-4
    ISSN 1477-0970 ; 1352-4585
    ISSN (online) 1477-0970
    ISSN 1352-4585
    DOI 10.1177/1352458519872897
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: A Proposed Approach to Screening and Surveillance Labs for Patients With Multiple Sclerosis on Anti-CD20 Therapy.

    Gandelman, Stephanie / Lenzi, Kerry A / Markowitz, Clyde / Berger, Joseph R

    Neurology. Clinical practice

    2024  Volume 14, Issue 1, Page(s) e200241

    Abstract: Background: Anti-CD20 therapies have proven to be highly effective and safe therapies for multiple sclerosis (MS) and have had rapid uptake in the MS community. However, no clear consensus has arisen regarding an approach to screening or surveillance ... ...

    Abstract Background: Anti-CD20 therapies have proven to be highly effective and safe therapies for multiple sclerosis (MS) and have had rapid uptake in the MS community. However, no clear consensus has arisen regarding an approach to screening or surveillance lab monitoring.
    Recent findings: Based on current evidence, for screening labs before anti-CD20 initiation, we propose checking liver function test (LFT), complete blood count with differential (CBC), absolute B-cell count, quantitative immunoglobulins, hepatitis B virus serologies, varicella zoster virus IgG, John Cunningham virus (JCV) status, and age-appropriate vaccination history. For surveillance monitoring in an otherwise asymptomatic individual, we propose biannual LFTs and CBC, quantitative immunoglobulins annually after year 3, absolute B-cell count at month 6 and in the setting of relapse, and JCV only if clinical or radiographic features of progressive multifocal leukoencephalopathy arise. For ublituximab, pregnancy testing is additionally recommended before each infusion.
    Implications for practice: We propose evidence-based screening and safety surveillance labs which take into account likelihood of changing management in an otherwise stable or asymptomatic individual.
    Language English
    Publishing date 2024-01-04
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2645818-4
    ISSN 2163-0933 ; 2163-0402
    ISSN (online) 2163-0933
    ISSN 2163-0402
    DOI 10.1212/CPJ.0000000000200241
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: The elimination of circulating Epstein-Barr virus infected B cells underlies anti-CD20 monoclonal antibody activity in multiple sclerosis: A hypothesis.

    Berger, Joseph R / Kakara, Mihir

    Multiple sclerosis and related disorders

    2022  Volume 59, Page(s) 103678

    Abstract: Multiple sclerosis is a chronic immune-mediated disease of the central nervous system that has aspects of repetitive inflammatory activity as well as a slow neurodegenerative process. The immune assault on the nervous system is triggered by a complex ... ...

    Abstract Multiple sclerosis is a chronic immune-mediated disease of the central nervous system that has aspects of repetitive inflammatory activity as well as a slow neurodegenerative process. The immune assault on the nervous system is triggered by a complex interaction between immunogenetic and environmental factors. Among the different environmental factors, a compelling case, buttressed by strong epidemiological, serological and other data, has been made for the role of Epstein-Barr virus (EBV) in the pathogenesis of MS. However, the ubiquity of EBV, lack of a well understood role in MS pathogenesis, and controversies regarding its presence in brains of people with MS has caused debate as to how exactly it contributes to MS. Recent years have seen the remarkable effect of anti-CD20 therapies on the inflammatory component of MS. How B cell depletion results in a salutary effect in MS remains incompletely understood. It has been proposed that depletion of CD20+ B-cells disrupts other pro-inflammatory pathways in the immune system, especially T-cells. In this paper, we make the case that the robust effect of anti-CD20 therapies on MS activity could actually be from removal of circulating EBV-infected memory B-cells that drive CNS inflammation and not through other immune pathways - in essence that this is from an anti-viral effect, and not necessarily an immuno-modulatory effect.
    MeSH term(s) Antibodies, Monoclonal ; B-Lymphocytes ; Epstein-Barr Virus Infections/complications ; Herpesvirus 4, Human ; Humans ; Multiple Sclerosis/pathology
    Chemical Substances Antibodies, Monoclonal
    Language English
    Publishing date 2022-02-07
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 2645330-7
    ISSN 2211-0356 ; 2211-0348
    ISSN (online) 2211-0356
    ISSN 2211-0348
    DOI 10.1016/j.msard.2022.103678
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top